Nitazene Control Act

Bill Number

S. 3076

Origin Chamber

Senate

Congress

119th Congress, Session 1

Policy Area

Crime and Law Enforcement

Status

Introduced

Latest Action

2025-10-30: Read twice and referred to the Committee on the Judiciary.

Last Updated

2025-11-25T20:22:32Z

AI-Generated Summary

Purpose

The Nitazene Control Act aims to permanently classify a group of synthetic opioids known as 2-benzylbenzimidazole opioids (commonly called nitazenes) under Schedule I of the Controlled Substances Act. This classification treats them as substances with high potential for abuse and no accepted medical use, helping to prevent their spread in the illicit drug market and address overdose risks.

Key Provisions

• Findings Section: Congress recognizes nitazenes as highly potent synthetic opioids (some stronger than fentanyl) first developed in the 1950s. It notes their role in illicit drugs causing overdoses, the Drug Enforcement Administration's (DEA) prior temporary scheduling of some under Schedule I, and the need for broad, permanent controls to block new variants. It also references the HALT Fentanyl Act, which allows research on Schedule I drugs under certain conditions.
• Schedule I Amendment: Adds a new category to Schedule I of the Controlled Substances Act covering any material containing 2-benzylbenzimidazole opioids, including their salts, isomers, and mixtures. Defines the class broadly to include:
• Structurally modified versions with specific substitutions (e.g., at positions 1, 2, and 6 of the chemical structure, such as adding alkyl groups or replacing parts with other atoms or rings).
• Substances that activate the mu-opioid receptor (the brain's main pain-relief target, explaining their addictive effects).
• Specific named compounds like etonitazene, clonitazene, metonitazene, and others.
• Permanent Scheduling: Converts any previously temporarily scheduled nitazenes to permanent Schedule I status upon enactment.
• Research Rule: Clarifies that new research on these substances requires proper DEA registration and compliance; it does not automatically allow unrestricted studies.

Significant Changes to Existing Law

• Shifts from temporary (emergency) scheduling under the Controlled Substances Act to permanent, class-wide inclusion in Schedule I, which preempts the creation and sale of new chemical analogs without needing repeated DEA actions.
• Expands Schedule I definitions to cover a broader range of structural variations, making enforcement more proactive against "designer drugs" that evade prior listings.
• Builds on the HALT Fentanyl Act by applying its research pathways to nitazenes, but adds safeguards to prevent misuse.

Potential Impacts

• Government Agencies: Strengthens the DEA's and law enforcement's ability to seize and prosecute nitazene-related activities, streamlining investigations and reducing administrative burdens from frequent rescheduling. Public health agencies like the Centers for Disease Control and Prevention may see fewer overdose cases from these drugs.
• Citizens: Reduces access to highly dangerous synthetic opioids in the illegal market, potentially lowering overdose deaths (nitazenes have contributed to fatal poisonings). However, it may increase penalties for possession or use, affecting individuals struggling with addiction.
• International Relations: Could enhance U.S. cooperation with other countries on global drug trafficking controls, as nitazenes often originate from international synthetic drug networks, but may strain relations if it leads to stricter border enforcement.

Main Stakeholders Affected

• Law Enforcement and Regulators: DEA, local police, and border agencies gain clearer tools for enforcement.
• Public Health and Medical Community: Overdose victims, addiction treatment providers, and researchers (who must now register for studies) are directly impacted.
• Citizens and Communities: People at risk of opioid addiction or accidental exposure, particularly in areas with high drug trafficking.
• Pharmaceutical and Chemical Industries: Companies dealing in related chemicals face stricter oversight to avoid accidental inclusion of controlled substances.

Notable Legal, Constitutional, or Political Implications

• Legal: Reinforces the federal government's authority under the Controlled Substances Act to regulate emerging threats, potentially reducing court challenges over analog drugs by providing a clear class definition. Ensures compliance with due process by maintaining research exceptions.
• Constitutional: Aligns with Congress's commerce clause powers to regulate interstate drug trade; no apparent conflicts with individual rights, though it could indirectly affect Fourth Amendment searches in drug enforcement.
• Political: Supports bipartisan efforts to combat the opioid crisis (introduced by senators from both parties), signaling a proactive stance on public health without introducing new funding or programs. May influence future drug policy by setting a precedent for class-wide scheduling of synthetic threats.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Sen. McCormick, David [R-PA]

Cosponsors (6)

Sen. Gallego, Ruben [D-AZ], Sen. Ricketts, Pete [R-NE], Sen. Shaheen, Jeanne [D-NH], Sen. Schmitt, Eric [R-MO], Sen. Slotkin, Elissa [D-MI], Sen. Moody, Ashley [R-FL]

Recent Actions

• 2025-10-30: Read twice and referred to the Committee on the Judiciary.
• 2025-10-30: Introduced in Senate

Bill Versions

• Nitazene Control Act — issued 2025-10-30 — PDF (5 pages)